AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
AxoGen, Inc.NASDAQ: AXGN
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow growth accelerates
Q3 FY2026 financing cash flow of $228.71M rose 9453.6% year over year, ahead of the +4152.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 29875.5% from the prior quarter. Over 3 fiscal years it compounded at +80.2% a year.
Context
- Financing cash flow amounted to 4.7% of revenue in FY2025, up 3.4 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +9453.6% holds above the trailing-twelve-month pace of +4152.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 10.5M USD
- Year-over-year change
- +358.5%
- 4-year CAGR
- -15.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.5M | +358.5% |
| FY2024 | 2024-12-31 | 2.29M | +17.2% |
| FY2023 | 2023-12-31 | 1.95M | +8.9% |
| FY2022 | 2022-12-31 | 1.79M | -91.2% |
| FY2021 | 2021-12-31 | 20.45M | — |
Financing Cash Flow vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's LTM Sep 2026 financing cash flow of $293.55M is the largest of the 7 companies compared; the peer median is $3.2M.
- Its year-over-year change of +4152.5% is the highest of 7, against a peer median of -50.8%.
- Financing cash flow amounts to 110.0% of revenue for AXGN, versus a peer median of 18.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $293.55M | +4152.5% | +80.2% | 110.0% | |
| LTM Mar 2026 | $38.07M | -61.2% | — | 1888.3% | |
| LTM Mar 2026 | $35.52M | -226.0% | +99.1% | 6.9% | |
| LTM Jun 2026 | $25.56M | -40.4% | -14.3% | 32.0% | |
| LTM Mar 2026 | $21.93M | -319.8% | — | 18.0% | |
| LTM Mar 2026 | $5.12M | +41.8% | +110.5% | 1.3% | |
| LTM Jun 2026 | $1.28M | +52.5% | — | — | |
| Peer median (excluding AXGN) | $3.2M | -50.8% | +99.1% | 18.0% | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Depreciation & Amortization | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M |
| Deferred Income Tax | 3.37M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.92M | 15.59M | 14.42M | 15.91M | 30.11M |
| Change in Working Capital | (6.28M) | (9.56M) | (4.39M) | (10.04M) | (24.62M) |
| Accounts Receivables | (499K) | (4.64M) | (2.69M) | 392K | (2.46M) |
| Inventory | (7.48M) | (3.66M) | (6.05M) | (10.16M) | (9.19M) |
| Accounts Payables | (270K) | 660K | 6.51M | 125K | (7.16M) |
| Other Working Capital | 1.97M | (1.93M) | (2.15M) | (399K) | (5.81M) |
| Other Non-Cash Items | 831K | 2M | 415K | 797K | 2.83M |
| Operating Cash Flow | (13.41M) | (16.07M) | (5.72M) | 4.54M | 812K |
| Capital Expenditures | (28.4M) | (21.25M) | (14.92M) | (4.52M) | (3.75M) |
| Acquisitions (Net) | (589K) | 3.2M | 0 | 0 | 0 |
| Purchases of Investments | (68.7M) | (39.25M) | (10.2M) | (5.77M) | (13.72M) |
| Sales of Investments | 72.5M | 57.3M | 44.37M | 0 | 14M |
| Other Investing Activities | 1.54M | (3.2M) | (1.05M) | (1.42M) | (1.85M) |
| Investing Cash Flow | (23.65M) | (3.2M) | 19.25M | (10.3M) | (5.32M) |
| Debt Repayment | 14.99M | (12K) | (10K) | (10K) | (32K) |
| Common Stock Issued | 5.47M | 1.81M | 1.96M | 2.3M | 10.53M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 20.45M | 1.79M | 1.95M | 2.29M | 10.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.6M) | (17.47M) | 15.49M | (3.47M) | 5.99M |
| Free Cash Flow | (41.81M) | (37.32M) | (20.63M) | 11K | (2.93M) |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.